Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6063798 | 1.00 | MAPK1 (0.43) | MAPK1L3MBTL1NPC1HPGDRAB9A | |
| SCHEMBL6062841 | 0.91 | MAPK1 (0.44) | MAPK1L3MBTL1NPC1HPGDRAB9A | |
| SCHEMBL6689469 | 0.91 | MAPK1 (0.44) | MAPK1L3MBTL1NPC1HPGDRAB9A | |
| SCHEMBL6061813 | 0.84 | ALOX15 (0.45) | MAPK1L3MBTL1NPC1HPGDRAB9A | |
| SCHEMBL6675832 | 0.84 | ALOX15 (0.45) | MAPK1L3MBTL1NPC1HPGDRAB9A | |
| SCHEMBL6655534 | 0.84 | MAPK1 (0.41) | MAPK1L3MBTL1NPC1HPGDRAB9A | |
| SCHEMBL6063009 | 0.84 | MAPK1 (0.41) | MAPK1L3MBTL1NPC1HPGDRAB9A | |
| SCHEMBL6655538 | 0.84 | MAPK1 (0.41) | MAPK1L3MBTL1NPC1HPGDRAB9A | |
| SCHEMBL6678152 | 0.83 | CTSS (0.42) | — | |
| SCHEMBL6061818 | 0.83 | CTSS (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | claimed |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | MAPK1 3715/4885L3MBTL1 4113/4885NPC1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.